Avastin (bevacizumab) • Tagrisso (osimertinib) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (NCT01950390)

Phase 2

National Cancer Institute (NCI)

Active, not recruiting

Phase 2

National Cancer Institute (NCI)

Active, not recruiting

Last update posted :

02/24/2025

Initiation :

01/24/2014

Primary completion :

10/06/2021

Completion :

01/31/2026

BRAF

BRAF mutation • BRAF wild-type

Avastin (bevacizumab) • Yervoy (ipilimumab) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • CS1002 (ipilimumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)

Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study (NCT02997228)

Phase 3

National Cancer Institute (NCI)

Recruiting

Phase 3

National Cancer Institute (NCI)

Recruiting

Last update posted :

02/24/2025

Initiation :

01/19/2018

Primary completion :

06/01/2027

Completion :

06/01/2027

PD-L1 • MSI • MLH1 • MSH6 • MSH2

PD-L1 expression • BRAF V600E • MSI-H/dMMR

Avastin (bevacizumab) • Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer (ECOG-ACRIN 5103) (NCT00433511)

Phase 3

National Cancer Institute (NCI)

Active, not recruiting

Phase 3

National Cancer Institute (NCI)

Active, not recruiting

Last update posted :

02/20/2025

Initiation :

11/02/2007

Primary completion :

01/07/2014

Completion :

02/22/2025

HER-2 • ER

Avastin (bevacizumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • cyclophosphamide intravenous • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER) (NCT04607421)

Phase 3

Pfizer

Active, not recruiting

Phase 3

Pfizer

Active, not recruiting

Last update posted :

02/20/2025

Initiation :

12/21/2020

Primary completion :

01/06/2025

Completion :

12/24/2026

BRAF

BRAF V600E • BRAF V600

Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • capecitabine • Braftovi (encorafenib) • oxaliplatin • irinotecan • leucovorin calcium • Zirabev (bevacizumab-bvzr) • Khapzory (levoleucovorin) • levoleucovorin calcium

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (NCT00217737)

Phase 3

National Cancer Institute (NCI)

Active, not recruiting

Phase 3

National Cancer Institute (NCI)

Active, not recruiting

Last update posted :

02/14/2025

Initiation :

09/06/2005

Primary completion :

08/31/2025

Completion :

08/31/2025

MSI • MSH2

Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery (CALGB 40603) (NCT00861705)

Phase 2

National Cancer Institute (NCI)

Active, not recruiting

Phase 2

National Cancer Institute (NCI)

Active, not recruiting

Last update posted :

02/06/2025

Initiation :

05/15/2009

Primary completion :

08/01/2014

Completion :

02/22/2025

HER-2 • ER • PGR

HER-2 negative

Avastin (bevacizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • cyclophosphamide intravenous • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)

Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer (CALGB-40503) (NCT00601900)

Phase 3

National Cancer Institute (NCI)

Active, not recruiting

Phase 3

National Cancer Institute (NCI)

Active, not recruiting

Last update posted :

02/06/2025

Initiation :

09/24/2008

Primary completion :

06/30/2014

Completion :

05/30/2025

ER • PGR

ER expression

Avastin (bevacizumab) • letrozole • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Soltamox (tamoxifen citrate) • Vasforda (bevacizumab biosimilar)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)

Phase 2

National Cancer Institute (NCI)

Active, not recruiting

Phase 2

National Cancer Institute (NCI)

Active, not recruiting

Last update posted :

02/06/2025

Initiation :

08/17/2015

Primary completion :

12/31/2025

Completion :

12/31/2025

MSI • CD4

PD-L1 expression

Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • cisplatin • Mekinist (trametinib) • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • capecitabine • Talzenna (talazoparib) • Piqray (alpelisib) • enzalutamide • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • eribulin mesylate • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • methotrexate • Truqap (capivasertib) • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • carmustine • Erivedge (vismodegib) • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • melphalan • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • fludarabine IV • Zynyz (retifanlimab-dlwr) • avadomide (CC-122) • Ostarine (enobosarm) • vistusertib (AZD2014) • mesna • Myocet (non-pegylated liposomal doxorubicin) • vinblastine • lorvotuzumab mertansine (IMGN901) • Xofigo (radium Ra-223 dichloride) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ieramilimab (LAG525) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • levoleucovorin calcium • methotrexate IV • Pertuvia (pertuzumab biosimilar) • sapitinib (AZD8931) • Vasforda (bevacizumab biosimilar)

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCI-2018-01503) (NCT03587311)

Phase 2

National Cancer Institute (NCI)

Active, not recruiting

Phase 2

National Cancer Institute (NCI)

Active, not recruiting

Last update posted :

05/17/2024

Initiation :

10/12/2018

Primary completion :

10/21/2024

Completion :

10/21/2024

MSLN

MSLN positive

Avastin (bevacizumab) • paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • anetumab ravtansine (BAY 94-9343) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (NCT00977574)

Phase 2

National Cancer Institute (NCI)

Active, not recruiting

Phase 2

National Cancer Institute (NCI)

Active, not recruiting

Last update posted :

05/17/2024

Initiation :

09/14/2009

Primary completion :

01/31/2015

Completion :

03/06/2025

AKT1

Avastin (bevacizumab) • carboplatin • paclitaxel • temsirolimus • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Ixempra (ixabepilone) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • patupilone (EPO 906) • Vasforda (bevacizumab biosimilar)

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors (NCT02142803)

Phase 1

National Cancer Institute (NCI)

Active, not recruiting

Phase 1

National Cancer Institute (NCI)

Active, not recruiting

Last update posted :

03/01/2024

Initiation :

05/20/2014

Primary completion :

12/31/2020

Completion :

10/01/2024

BRAF

Avastin (bevacizumab) • sapanisertib (CB-228) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)

Zirabev (bevacizumab-bvzr)

Trials

Trials